Total
0
Shares
Avicanna Inc - CEO, Aras Azadian
CEO, Aras Azadian
Source: Small Cap Power
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Avicanna (AVCN) has filed a provisional patent application with the United States Patent and Trademark Office
  • The application is for the use of a new cannabinoid formulation shown to reduce the incidence of seizures and sudden death in epilepsy
  • Preliminary electrophysiological studies determined that treatment with the formulation candidate produced significant anticonvulsant effects
  • If granted, this patent application will provide Avicanna with protection on the use of the formulation candidate within a specified ratio of cannabinoids
  • Avicanna is a biopharmaceutical company focused on plant-derived cannabinoid-based products
  • Avicanna Inc. (AVCN) opened trading at C$0.97 per share

Avicanna (AVCN) has filed a provisional patent application with the United States Patent and Trademark Office.

The application is for the use of a new cannabinoid formulation shown to reduce the incidence of seizures and sudden death in epilepsy.

The research findings originated from the ongoing multi-level cannabinoid-based collaboration with leading epilepsy researcher Dr. Peter Carlen at the world-renowned Krembil Research Institute at the University Health Network.

Preliminary electrophysiological studies determined that treatment with the formulation candidate produced significant anticonvulsant effects as compared to treatment with cannabidiol or tetrahydrocannabinol alone.

These results suggest that, in addition to anti-convulsant properties, the Formulation Candidate demonstrates strong potential to treat patients diagnosed with intractable forms of epilepsies and at risk of seizure-induced Sudden Unexpected Death in Epilepsy. Further studies on the mechanism of action of the cannabinoids in the Formulation Candidate confirmed that the cannabinoids acted as selective 5-HT1A receptor agonists similar to established 5-HT1A receptor agonists in seizure-like events.

Aras Azadian, Chief Executive Officer of Avicanna, stated,

“Understanding the anti-convulsant properties of our proprietary formulation in seizure disorders is important particularly since this combination drug has potential to reduce the likelihood of seizure-induced sudden death in epilepsy. The exceptional research conducted by Dr. Carlen’s team with support from our R&D team, and the resulting patent submission will be a major driver for guiding our long-term drug and clinical development plans, particularly since its in the area with an existing FDA approved cannabinoid-based drug.”

Avicanna intends to conduct studies in the coming months in order to formalize this provisional application. If granted, this patent application will provide Avicanna with protection on the use of the formulation candidate within a specified ratio of cannabinoids, alone or in combination with other anti-epileptic agents.

Avicanna is a Canadian biopharmaceutical company focused on the research, development and commercialization of plant-derived cannabinoid-based products.

Avicanna Inc. (AVCN) opened trading at C$0.97 per share.

More From The Market Herald

" Andlauer Healthcare Group (TSX:AND) completes $169M bought deal offering

Andlauer Healthcare Group Inc. (AND) and Andlauer Management Group Inc. completed a bought deal offering of 3.5 million subordinate voting shares (SVSs).

" Avricore (TSXV:AVCR) expands HealthTab to select Shoppers Drug Mart locations in BC

Avricore Health (AVCR) has expanded its patient testing with the HealthTab platform in select Shoppers Drug Mart pharmacies in BC.

" Clearmind (CSE:CMND) signs development and supply agreement with Aragen Life Sciences

Clearmind Medicine (CMND) will work with Aragen Life Sciences to produce its innovative molecule, 5-Methoxy-2-aminoindane (MEAI).

" Aptose (TSX:APS) expands senior leadership team

Aptose Biosciences (TSX: APS) has appointed two key members to its management team to support its finance and operations functions.